8 Homegrown Indian Skincare Ingredients That Urgently Need Clinical Research and Funding

In 2018, a randomised controlled trial published in the British Journal of Dermatology by Dhaliwal et al. compared bakuchiol, extracted from the seeds of Psoralea corylifolia, a plant used in Ayurvedic medicine for centuries, with 0.025% retinol. Bakuchiol matched retinol on wrinkle reduction and pigmentation improvement with significantly fewer side effects. That study was conducted by researchers in the UK. Indian dermatological institutions have produced almost no follow-up clinical work on standardised bakuchiol formulations, dosage thresholds, or long-term skin barrier effects. The ingredient now sells at a premium in Western clean beauty markets. The research infrastructure that would allow Indian manufacturers to make evidence-backed formulation claims remains largely absent.

Rubia cordifolia, called manjistha in classical Ayurvedic texts, has been used as a blood purifier and skin brightener for well over a thousand years. Its active compounds, purpurin, munjistin, and pseudopurpurin, have demonstrated anti-inflammatory and antioxidant activity in in-vitro studies. The gap is everything beyond that. There are no published Phase II or Phase III clinical trials examining manjistha's topical efficacy for hyperpigmentation, acne, or post-inflammatory erythema in human subjects. For an ingredient this old and this widely used in Indian household skincare practice, that absence is a research failure, not a knowledge failure. The traditional use data is extensive. The clinical translation has simply never been funded.

Kokum butter, pressed from the seeds of Garcinia indica grown along the Konkan coast, has a fatty acid composition that cosmetic chemists outside India find genuinely interesting: it is high in stearic and oleic acids, has a sharp melting point close to body temperature, and is non-comedogenic in empirical use. Indian coastal communities have used it on skin and hair for generations. What does not exist is a peer-reviewed clinical study examining its transepidermal water loss effects, its comedogenicity score in a controlled trial, or its comparative efficacy against shea butter for dry or eczema-prone skin. Without that data, Indian botanical brands cannot make the label claims that would let them compete in regulated export markets. The ingredient stays regional while the research that would globalise it stays unfunded.

Turmeric is the most-studied Indian skincare ingredient by volume. The problem is that the bulk of curcumin research addresses oral bioavailability, anti-inflammatory pathways in gut and joint tissue, and cancer biology. Topical curcumin for dermatological applications, wound healing, psoriasis, acne vulgaris, photoprotection, has a much thinner evidence base, and the studies that do exist rarely address the core formulation challenge: curcumin's poor skin penetration due to its large molecular size and hydrophobicity. A 2016 review in BioFactors by Vollono et al. acknowledged the dermatological potential while flagging the delivery problem as the primary barrier to clinical use. Indian research institutions are well-positioned to solve this, given access to raw material, traditional knowledge of turmeric preparations, and existing phytochemistry expertise. The funding to pursue it has not matched the ingredient's profile.

Phyllanthus emblica, or amla, has one of the highest natural concentrations of Vitamin C of any fruit, a fact established in nutritional science. Its antioxidant capacity is documented. What the clinical literature lacks is a body of work on standardised topical amla extract: stable formulations that preserve the Vitamin C content through the manufacturing process, comparative studies against ascorbic acid serums, and long-term trials on photoaging in Indian skin tones specifically. Indian skin tones have distinct melanin distribution patterns that affect how active ingredients perform, a fact that Western clinical trials routinely ignore by default. Amla research conducted on Indian subjects, with formulations designed for Indian skin, would produce findings more directly applicable to the actual consumer using the product. That research is not happening at scale.

Symplocos racemosa, known as lodhra, appears in Charaka Samhita and Sushruta Samhita as a treatment for skin disorders, inflammation, and wound healing. Its bark contains saponins, flavonoids, and loturine alkaloids. In-vitro data suggests anti-inflammatory and astringent properties. Beyond that, the clinical record is essentially blank. No randomised trials. No safety profile established for cosmetic concentrations. No dermatologist-led study on its effect on sebum regulation or pore appearance. Lodhra represents the furthest end of the research gap: an ingredient with centuries of documented traditional use, plausible biochemical mechanisms, and zero clinical translation. If it were a synthetic compound with the same in-vitro profile, it would already be in Phase I trials somewhere. Because it is a botanical with no patent potential and no multinational sponsor, it waits.

The pattern across all six ingredients is the same: traditional use data that constitutes decades of real-world safety observation, in-vitro findings that justify clinical investment, and a funding structure that routes money toward patentable synthetics rather than public-domain botanicals. India has the raw material, the traditional knowledge systems, and the dermatological research capacity. What is missing is a funding mechanism that treats these ingredients as scientific questions worth answering, not just as marketing language for labels.